Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
First in class study of an investigational ACTH receptor antagonist aims to…
Looking Ahead in 2026: Datatonic Examines the Next Phase of Enterprise AI as Focus Shifts from Pilots to ROI
In 2026, AI investment is shifting from experimentation to deployment, with measurable…
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for…
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Company to host conference call and webcast on Tuesday, January 20, 2026…
New site in Lommel, Belgium: Aqua free successfully completes set-up phase with ISO 9001 certification
Lommel / Hamburg, 01/15/2026 – Aqua free, a leading provider of innovative drinking-water…
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
— First randomized Phase III trial confirming the efficacy of MET inhibition…
Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
Not intended for US and UK audiences BI 765423 has been developed…
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up…
LIfT BioSciences Announces CEO Transition to Drive Next Phase of Growth with Neutrophil-based Therapies
Dr. Bo Rode Hansen, current Board member and Corporate Development Officer named…
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
January 04, 2026 16:00 ET | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO,…
